A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms development

Atherosclerosis

Volumn 242, Issue 2, 2015, Pages 563-570

  Huggins, Christopher ^a   Pearce, Stuart ^a   Peri, Francesco ^b   Neumann, Frank ^c   Cockerill, Gillian ^a   Pirianov, Grisha ^d  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c Innaxon   (United Kingdom)

^d ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

Author keywords

Experimental aneurysms; Toll like receptor 4; Toll like receptor 4 antagonist IAXO 102; Vascular inflammation

Indexed keywords

ANGIOTENSIN II; IAXO 102; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN INHIBITOR; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; AMINOSUGAR; APOLIPOPROTEIN E; GLYCOLIPID; IAXO-102; TLR4 PROTEIN, HUMAN;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INCIDENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTIC ANEURYSM, ABDOMINAL; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION;

AMINO SUGARS; ANIMALS; AORTA; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GLYCOLIPIDS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INCIDENCE; INFLAMMATION; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA;

EID: 84939863187     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.08.010     Document Type: Article

References (38)

1. Svensjö S., Björck M., Wanhainen A. Update on screening for abdominal aortic aneurysm: a topical review. Eur. J. Vasc. Endovasc. Surg. 2014, 48:659-667. 10.1016/j.ejvs.2014.08.029.
2. Saraff K., Babamusta F., Cassis L.A., Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1621-1626. 10.1161/01.ATV.0000085631.76095.64.
3. Ohashi K., Burkart V., Flohé S., Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 2000, 164:558-561.
4. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 2001, 276:10229-10233. 10.1074/jbc.M100099200.
5. Suganami T., Tanimoto-Koyama K., Nishida J., Itoh M., Yuan X., Mizuarai S., et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 2007, 27:84-91. 10.1161/01.ATV.0000251608.09329.9a.
6. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103-3108.
7. Edfeldt K., Swedenborg J., Hansson G.K., Yan Z. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002, 105:1158-1161.
8. Owens A.P., Rateri D.L., Howatt D.A., Moore K.J., Tobias P.S., Curtiss L.K., et al. MyD88 deficiency attenuates angiotensin II-induced abdominal aortic aneurysm formation independent of signaling through Toll-like receptors 2 and 4. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2813-2819. 10.1161/ATVBAHA.111.238642.
9. Michelsen K.S., Wong M.H., Shah P.K., Zhang W., Yano J., Doherty T.M., et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10679-10684. 10.1073/pnas.0403249101.
10. Timmers L., Sluijter J.P.G., van Keulen J.K., Hoefer I.E., Nederhoff M.G.J., Goumans M.-J., et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ. Res. 2008, 102:257-264. 10.1161/CIRCRESAHA.107.158220.
11. Salluh J.I.F., Póvoa P. Biomarkers as end points in clinical trials of severe sepsis: a garden of forking paths. Crit. Care Med. 2010, 38:1749-1751. 10.1097/CCM.0b013e3181e941f6.
12. Kalil A.C., LaRosa S.P., Gogate J., Lynn M., Opal S.M. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock 2011, 36:327-331. 10.1097/SHK.0b013e318227980e.
13. Piazza M., Rossini C., Della Fiorentina S., Pozzi C., Comelli F., Bettoni I., et al. Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization. J. Med. Chem. 2009, 52:1209-1213. 10.1021/jm801333m.
14. Lonez C., Vandenbranden M., Ruysschaert J.-M. Cationic lipids activate intracellular signaling pathways. Adv. Drug Deliv. Rev. 2012, 64:1749-1758. 10.1016/j.addr.2012.05.009.
15. Piazza M., Yu L., Teghanemt A., Gioannini T., Weiss J., Peri F. Evidence of a specific interaction between new synthetic antisepsis agents and CD14. Biochemistry 2009, 48:12337-12344. 10.1021/bi901601b.
16. Bettoni I., Comelli F., Rossini C., Granucci F., Giagnoni G., Peri F., et al. Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia 2008, 56:1312-1319. 10.1002/glia.20699.
17. Peri F., Piazza M., Calabrese V., Damore G., Cighetti R. Exploring the LPS/TLR4 signal pathway with small molecules. Biochem. Soc. Trans. 2010, 38:1390-1395. 10.1042/BST0381390.
18. Jones A., Deb R., Torsney E., Howe F., Dunkley M., Gnaneswaran Y., et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation 2009, 119:3125-3132. 10.1161/CIRCULATIONAHA.109.852467.
19. Makó V., Czúcz J., Weiszhár Z., Herczenik E., Matkó J., Prohászka Z., et al. Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS. Cytom. A 2010, 77:962-970. 10.1002/cyto.a.20952.
20. Pirianov G., Torsney E., Howe F., Cockerill G.W. Rosiglitazone negatively regulates c-Jun N-terminal kinase and toll-like receptor 4 proinflammatory signalling during initiation of experimental aortic aneurysms. Atherosclerosis 2012, 225:69-75. 10.1016/j.atherosclerosis.2012.07.034.
21. Torsney E., Pirianov G., Charolidi N., Shoreim A., Gaze D., Petrova S., et al. Elevation of plasma high-density lipoproteins inhibits development of experimental abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2678-2686. 10.1161/ATVBAHA.112.00009.
22. Moghimpour Bijani F., Vallejo J.G., Rezaei N. Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities. Int. Rev. Immunol. 2012, 31:379-395. 10.3109/08830185.2012.706761.
23. Daugherty A., Cassis L. Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med. 2004, 14:117-120. 10.1016/j.tcm.2004.01.002.
24. Hałupka-Bryl M., Asai K., Thangavel S., Bednarowicz M., Krzyminiewski R., Nagasaki Y. Synthesis and in vitro and in vivo evaluations of poly(ethylene glycol)-block-poly(4-vinylbenzylphosphonate) magnetic nanoparticles containing doxorubicin as a potential targeted drug delivery system. Colloids Surf. B Biointerfaces 2014, 118:140-147. 10.1016/j.colsurfb.2014.03.025.
25. Trzpis K, Kasprzycka E, Skotnicka B, Hassmann-Poznańska E, Wysocka J, Expression of Toll-like receptors on peripheral blood white cells in acute otitis media, Otolaryngol Pol n.d.;68:77-82. doi:10.1016/j.otpol.2013.06.006.
26. Peri F., Calabrese V. Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update. J. Med. Chem. 2014, 57:3612-3622. 10.1021/jm401006s.
27. Manning M.W., Cassi L.A., Huang J., Szilvassy S.J., Daugherty A. Abdominal aortic aneurysms: fresh insights from a novel animal model of the disease. Vasc. Med. 2002, 7:45-54.
28. Cho A., Graves J., Reidy M.A. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2527-2532.
29. Yoshimura K., Aoki H., Ikeda Y., Furutani A., Hamano K., Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase in mice. Ann. N. Y. Acad. Sci. 2006, 1085:74-81. 10.1196/annals.1383.031.
30. Kubarenko A., Frank M., Weber A.N.R. Structure-function relationships of Toll-like receptor domains through homology modelling and molecular dynamics. Biochem. Soc. Trans. 2007, 35:1515-1518. 10.1042/BST0351515.
31. Daugherty A., Manning M.W., Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 2000, 105:1605-1612. 10.1172/JCI7818.
32. Trivedi D.B., Loftin C.D., Clark J., Myers P., DeGraff L.M., Cheng J., et al. β-Arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice. Circ. Res. 2013, 112:1219-1229. 10.1161/CIRCRESAHA.112.280399.
33. Wang Y., Ait-Oufella H., Herbin O., Bonnin P., Ramkhelawon B., Taleb S., et al. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J. Clin. Invest. 2010, 120:422-432. 10.1172/JCI38136.
34. Naiki Y., Michelsen K.S., Zhang W., Chen S., Doherty T.M., Arditi M. Transforming growth factor-beta differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J. Biol. Chem. 2005, 280:5491-5495. 10.1074/jbc.C400503200.
35. Feng Y., Cai Z.R., Tang Y., Hu G., Lu J., He D., et al. TLR4/NF-κB signaling pathway-mediated and oxLDL-induced up-regulation of LOX-1, MCP-1, and VCAM-1 expressions in human umbilical vein endothelial cells. Genet. Mol. Res. 2014, 13:680-695. 10.4238/2014.January.28.13.
36. Taylor K.R., Trowbridge J.M., Rudisill J.A., Termeer C.C., Simon J.C., Gallo R.L. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J. Biol. Chem. 2004, 279:17079-17084. 10.1074/jbc.M310859200.
37. Zheng Y., Gardner S.E., Clarke M.C.H. Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2781-2786. 10.1161/ATVBAHA.111.224907.
38. Shang T., Ran F., Qiao Q., Liu Z., Liu C.-J. Tanshinone IIA attenuates elastase-induced AAA in rats via inhibition of MyD88-dependent TLR-4 signaling. Vasa 2014, 43:39-46. 10.1024/0301-1526/a000326.